Table 3.
Growth Inhibition of Pancreatic Cancer Cells by Selected Maleimides
| Compound | IC50 (μM) ± SD |
||
|---|---|---|---|
| MiaPaCa-2[a] | BXPC3[a] | HupT3[a] | |
| 77 | 29.0 ± 1.7 | 14.0 ± 0.6 | 22.0 ± 2.1 |
| 78 | 25.0 ± 0.9 | NT[b] | NT[b] |
| 5 | 0.6 ± 0.1 | 0.9 ± 0.2 | 0.6 ± 0.1 |
| 6 | 3.0 ± 0.4 | 2.0 ± 0.2 | 2.0 ± 0.3 |
| 7 | 7 ± 1 | 5.0 ± 0.7 | 2.1 ± 1.5 |
| 11 | 3.0 ± 0.2 | 1.0 ±0.2 | 1.0 ± 0.1 |
| 13 | 30.0 ± 2.2 | NT[b] | 43.0 ± 6.3 |
| 20 | 2.0 ± 0.2 | 0.9 ± 0.1 | 2.0 ± 0.1 |
| 21 | 8.0 ± 0.6 | 33 ± 4 | > 50 |
| 22 | 28.0 ± 4.1 | 42.0 ± 7.6 | 42.0 ± 8.3 |
| 25 | 34.0 ± 2.2 | > 50 | > 50 |
| 26 | 5.0 ± 0.9 | 1.0 ± 0.2 | 0.6 ± 0.1 |
| 27 | > 50 | > 50 | > 50 |
| 30 | 8.0 ± 1.2 | 6.0 ± 0.8 | 6.0 ± 0.5 |
| 33 | > 50 | > 50 | 27.0 ± 4.2 |
| 38 | 17.0 ± 3.2 | 7.0 ± 2.1 | 6.0 ± 0.7 |
[a]
The pancreatic cancer cell lines MiaPaCa-2, BXPC3 and HupT3 were obtained from ATCC (Rockville, MD). MTS assay was carried out according to the manufacturer protocol. 72 Hours post-treatment, cell viability was measured and compounds IC50 values were determined
[b]
Not tested.